ReviewCancers2024
Historical Perspective and Current Trends in Anticancer Drug Development.
Review in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Goniothalamin as a Styryl-Lactone Toxicophore in Cancer Models: Electrophile-Driven DNA Damage, Reactive Oxygen Species-Endoplasmic Reticulum Stress Signaling and Detoxification-Relevant Safety Considerations.Journal of biochemical and molecular toxicology · 2026Review
- Synthesis, computational studies, and biological evaluation of novel cyanoacrylamides as potential anticancer agents.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Computational Density Functional Theory and Kinetic-Thermodynamic Stable Crown-Chair Conformers of Hydroxyphenyl Calix[4]resorcinarene Macrocycles: Molecular Docking, Antioxidant, Antibacterial and Photophysical Applications.Journal of fluorescence · 2026Article
- Thiazole-Derived Dual EGFR/CDK-2 Inhibitors: Rational Design, Synthesis, In Vitro Anticancer Evaluation, Mechanistic Profiling, and Computational Binding Analysis.Archiv der Pharmazie · 2026Article
- Dammarenediol II enhances etoposide-induced apoptosis by targeting O-GlcNAc transferase and Akt/GSK3β/mTOR signaling in liver cancer.Molecular oncology · 2026Article
- Evaluation of the Pharmacological Potential ofPharmaceuticals (Basel, Switzerland) · 2026Article
- Advances in natural product discovery: strategies, technologies, and insights.Natural products and bioprospecting · 2026Review
- Anticancer Secondary Metabolites Produced by Fungi: Potential and Representative Compounds.International journal of molecular sciences · 2025Review
- Synthesis and anticancer potential of glycosides.RSC advances · 2025Review
- The Role of Platinum-Based Chemotherapy in the Pathogenesis of Tendinosis in Cancer Patients.Cureus · 2025Review
- Review
- Targeting Prostate Cancer Metabolism Through Transcriptional and Epigenetic Modulation: A Multi-Target Approach to Therapeutic Innovation.International journal of molecular sciences · 2025Review
- Plant Alkaloids as Promising Anticancer Compounds with Blood-Brain Barrier Penetration in the Treatment of Glioblastoma: In Vitro and In Vivo Models.Molecules (Basel, Switzerland) · 2025Review
- Substituted 1,4-naphthoquinones for potential anticancer therapeutics:Computational and structural biotechnology journal · 2025Article
- Camptothecin and its derivatives: Advancements, mechanisms and clinical potential in cancer therapy.Medical oncology (Northwood, London, England) · 2024Review
- Cytotoxicity and molecular docking analysis of phytochemicals fromBioinformation · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Cancer is considered one of the leading causes of death in the 21st century. The intensive search for new anticancer drugs has been actively pursued by chemists and pharmacologists for decades, focusing either on the isolation of compounds with cytotoxic properties from plants or on screening thousands of synthetic molecules. Compounds that could potentially become candidates for new anticancer drugs must have the ability to inhibit proliferation and/or induce apoptosis in cancer cells without causing too much damage to normal cells. Some anticancer compounds were discovered by accident, others as a result of long-term research. In this review, we have presented a brief history of the development of the most important groups of anticancer drugs, pointing to the fact that they all have many side effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.